WO1997011061A1 - Composes a potentialisation de retinoide - Google Patents
Composes a potentialisation de retinoide Download PDFInfo
- Publication number
- WO1997011061A1 WO1997011061A1 PCT/JP1996/002709 JP9602709W WO9711061A1 WO 1997011061 A1 WO1997011061 A1 WO 1997011061A1 JP 9602709 W JP9602709 W JP 9602709W WO 9711061 A1 WO9711061 A1 WO 9711061A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- hexano
- dimethyl
- group
- benzoic acid
- Prior art date
Links
- 0 CC(C)(CCC(C)(C)c1c2)c1cc(C(c(cc1)ccc1C(OC)=O)=*C1)c2NC1=O Chemical compound CC(C)(CCC(C)(C)c1c2)c1cc(C(c(cc1)ccc1C(OC)=O)=*C1)c2NC1=O 0.000 description 2
- MIPNSMBCJILFGD-UHFFFAOYSA-N CC(C)(CCC(C)(C)c1c2)c1cc(C(c(cc1)ccc1C(O)=O)=NC1)c2N(C)C1=O Chemical compound CC(C)(CCC(C)(C)c1c2)c1cc(C(c(cc1)ccc1C(O)=O)=NC1)c2N(C)C1=O MIPNSMBCJILFGD-UHFFFAOYSA-N 0.000 description 1
- WYLNMBAYOZMJOT-SANMLTNESA-N CC(C)(CCC(C)(C)c1c2)c1cc(C(c(cc1)ccc1C(O)=O)=N[C@H]1Cc3ccccc3)c2N(C)C1=O Chemical compound CC(C)(CCC(C)(C)c1c2)c1cc(C(c(cc1)ccc1C(O)=O)=N[C@H]1Cc3ccccc3)c2N(C)C1=O WYLNMBAYOZMJOT-SANMLTNESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/38—[b, e]- or [b, f]-condensed with six-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D267/20—[b, f]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D281/16—[b, f]-condensed
Definitions
- the present invention relates to a novel compound, and more particularly to a novel compound that enhances the physiological action of nuclear receptor receptor, such as a compound having retinoic acid-retinoic acid-like physiological activity (retinoide). is there.
- nuclear receptor receptor such as a compound having retinoic acid-retinoic acid-like physiological activity (retinoide).
- Retinoic acid is an active metabolite of vitamin A. It acts to differentiate developing immature cells into mature cells with unique functions, promote cell growth, It has extremely important physiological functions such as life support.
- vitamin A derivatives synthesized so far, for example, benzoic acid derivatives described in JP-A-61-22047 and JP-A-61-76440, and journal 'Ob' Median 'Chemistry The compounds described in Trial (Journal of Medicinal Chemistry, 1988, Vol. 31, No. 11, p. 2182) have been shown to have similar physiological effects.
- the above compounds having retinoic acid and retinoic acid-like biological activity are collectively referred to as "retinoides”.
- An object of the present invention is to provide a compound having an action of enhancing the action of retinoid such as retinoic acid. More specifically, it can significantly enhance the action of retinoids, such as retinoic acid, even though it has no retinoid action itself or its retinoid action is weak. It is an object of the present invention to provide compounds.
- R 1 represents a hydrogen atom or a _ 6 alkyl group
- R 2 and R 3 are each independently a hydrogen atom or a ( ⁇ -6 represents an alkyl group, or R 2 and together such connexion they exhibit a cycloalkyl ring also 5 or 6-membered having a completion alkyl group together with the carbon atoms on the Hue cycloalkenyl ring linked
- R 4 is a hydrogen atom, - 6 alkyl group, alkoxy group, hydroxyl group, nitro group, or a halogen atom
- R 5 is a hydrogen atom, ⁇ _ 6 alkyl group, or indicates Ariru substituted alkyl group
- R Q represents a hydrogen atom or a ( ⁇ _ 6 alkyl group
- X is - NR 7 -, -0-, -CHR or -S- (wherein R 7 represents a hydrogen atom, a 6- alkyl group or an aryl-substituted
- R 1 is.
- Alkyl group represents a hydrogen atom or a linear or minute technique chain ( ⁇ _ 6 (of 1 -C 6) alkyl group, e.g., methyl group, Echiru group , N-propyl group, isopropyl group, n-butyl group, sec-butyl group, tert-butyl group and the like, and preferably a methyl group.
- R 2 and R 3 Ku independently Wakashi hydrogen atom or a straight-chain shows a _ 6 alkyl min skill chain.
- the alkyl group for example, those exemplified above can be used, and preferably, an ethyl group, an isopropyl group, a tert-butyl group and the like can be used.
- the substitution position of R 2 and R 3 is not particularly limited, and can be substituted at any position at the same time, provided that R 2 and R 3 are para and meta positions with respect to X, respectively. It is preferred that R 2 and R 3 are respectively meta and ortho relative to X, and It is particularly preferred that R 3 is para and meta to X, respectively.
- R " 3 can be linked to form a 5- or 6-membered cycloalkyl ring together with the two carbon atoms on the phenyl ring to which R 2 and R 3 are bonded.
- the cycloalkyl ring may have one or two or more 4 alkyl groups, for example, it may have 2 to 4 methyl groups, preferably 4 methyl groups. . for example, by a phenyl ring and R 2 and R 3 wherein R 2 and R 3 are substituted, 5, 6, 7, 8-tetra-human mud naphthalene ring Ya 5, 5, 8, 8-te Bok Ramechiru -5, It is preferred that a 6, 7, 8-tetrahydrodronaphthalene ring or the like be formed.
- R 4 is a hydrogen atom, - 6 alkyl group, - showing 6 alkoxy group, hydroxyl group, nitro group, or a halogen atom.
- the alkyl group include those exemplified above.
- the alkoxy group include a methoxy group, an ethoxy group, an ⁇ -propoxy group, an isopropoxy group, an ⁇ -butoxy group, and a sec group.
- a -butoxy group, a tert-butoxy group, preferably a methoxy group, and the halogen atom may be any of a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom. Is not particularly limited and can be substituted at any position on the phenyl ring.
- R 5 is a hydrogen atom, (:. Bok 6 alkyl group, or as a _ 6 alkyl group represented by Ariru substituted _ 6 alkyl groups may be linear or branched, used in the prime apply those exemplified above
- the alkyl moiety may be either a straight chain or a branched chain, such as a benzyl group, phenyl substituted ( ⁇ _ 6 alkyl groups such as phenethyl, naphthyl substituted _ 6 alkyl groups such as naphthylmethyl group, and the like can be used pyridyl substituted ( ⁇ _ 6 alkyl groups such as pyridinium Jirumechiru group.
- the aryl group constituting the alkyl group may have one or more substituents, for example, a halogen atom such as a fluorine atom and a chlorine atom; ,
- a halogen atom such as a fluorine atom and a chlorine atom
- Such Echiru group ⁇ _ 6 alkyl group; main Bok alkoxy group, straight Kusariwaka properly such et butoxy group branched ( ⁇ _ 6 alkoxy group; a nitro group; a straight Zhen such Application Benefits Furuoromechiru group halogenated alkyl groups of young properly is branched, a hydroxyl group, a carboxyl group,.
- Bok alkyl The alkyl group may be either a straight chain or a branched chain, and those exemplified above can be suitably used.
- X is 'nitrogen atom substituted by a (- NR 7 -), an oxygen atom (- 0-), R' R show, or sulfur atom (_S-) methylcarbamoyl Ren group substituted with (- - CHR 7) .
- R 7 is a hydrogen atom, _ 6 alkyl group or Ariru substituted - shows the 6 alkyl group.
- the alkyl group may be either a straight chain or a branched chain, and those exemplified above, for example, a methyl group can be used.
- the nitrogen atom or sulfur atom may be N-oxide or sulfoxide, respectively.
- X is a nitrogen atom substituted with R 7 (NR '), particularly preferred are, X is a methyl group, Echiru group, n- propyl group, I an isopropyl group, or benzyl group This is the case where a substituted nitrogen atom is shown.
- Y represents a phenylene group or a pyridinyl group.
- An arbitrary phenylene group or a pyridinyl group such as a diyl group can be used, and a p-phenylene group, an in-phenylene group, or a pyridin-2,5-diyl group can be preferably used.
- Pyridinium Gin - 2, 5-Jiiru case of using group the 2-position or 5-position any position of the pyridinium Jin - groups represented by C00R 1 may be substituted.
- the compounds of the present invention include acid addition salts or base addition salts.
- the acid addition salt include a mineral acid salt such as hydrochloride or hydrobromide, or an organic acid salt such as p-toluenesulfonate, methanesulfonate, oxalate, or tartrate. it can.
- a base addition salt is formed when R 1 represents a hydrogen atom, and is a metal salt such as a sodium salt, a potassium salt, a magnesium salt, or a calcium salt, an ammonium salt, or a triethylamine salt or an ethanol salt.
- Organic amine salts such as amine salts can be used.
- the carbon atom which they substitute becomes an asymmetric carbon when and R 6 are different substituents, the carbon atom which they substitute becomes an asymmetric carbon.
- the 7-membered ring containing X Assuming a plane, either R 5 or R 6 may be above the plane.
- the compound of the formula (I) or the formula ( ⁇ ) of the present invention may further have one or more asymmetric carbons depending on the type of X or the substituent. Any optical isomers based on asymmetric carbons, arbitrary mixtures of optical isomers, racemates, diastereoisomers based on two or more asymmetric carbons, arbitrary mixtures of diastereoisomers, etc. Is included in the range. Also, needless to say, any hydrate or solvate of the compound in the form of a free compound or a salt is included in the scope of the present invention.
- a preferred compound is 4-H-2,3- (2,5-dimethyl-2,5-hexano) -5-methyldibenzo [b, e] [1,4] Dazepin-11-yl] benzoic acid (HX600);
- esters of each of the above compounds for example, methyl esters (for example, HX600 About methyl 4-H-2,3- (2,5-dimethyl-2,5-hexano) -5_methyldibenzo [b, e] [1, 4] diazepine_1 tril] benzo U);
- preferred compounds include, for example, compounds shown in the following table.
- R 1 is a hydrogen atom or a methyl group
- Y is a p_phenylene group
- X is —NR 7 —.
- Bzl represents a benzyl group
- the notations such as 7-Me, 8-Et, 8-i-Pro, and 9-1-Bu represent a methyl group at the 7-position of the compound represented by formula (II), respectively.
- 7- (CH 0) 4 - display such as 8 and 7- CiC ⁇ O ⁇ CH ⁇ CCH ⁇ o- 8 , respectively, the 7-position and 8-position of the compound represented by the formula ([pi) There - (CHO ⁇ - and - C (CH 3) 2 CH 2 CH 2 C (CH 0) 2 - indicating that the coupled in.
- Lower alkyl esters of the above compounds preferably methyl esters (for example, for HX800, methyl 4- [1,3-dihydro-7,8- (2,5-dimethyl-2,5-hexano) -2 -Kiso-2H-1,4-benzodiazepine-5-yl] -benzoate).
- the following scheme shows an example of a production method for HX600, HX610, HX511. HX531, and HX545, which are preferred compounds included in the formula (I) of the present invention.
- the following scheme shows an example of a similar production method for HX800, HX801, and HX850, which are preferred compounds included in the formula (II) of the present invention.
- the compound of the present invention and the method for producing the same are not limited to those shown in these schemes.
- the method for producing the compound of the present invention according to the following scheme is described in detail, so that the starting materials, reagents, reaction conditions, and the like shown in these methods are not appropriately modified or modified. It will be readily understood that by modification, any of the compounds falling within the scope of the invention can be prepared.
- the compound of the present invention is a compound which has substantially no retinoid-like action itself or has a weak or moderate retinoid-like action.
- a retinoid such as retinoic acid
- the physiological activity of the retinoid is markedly enhanced. Is done.
- the compound of the present invention is a compound of the above type having a retinoic acid-retinoic acid-like biological activity (for example, 4-[(5,6,7,8-tetrahydro-5,5,8,8 -tetramethyl-2-naphthalenyl) carbamoy ⁇ ”benzoic acid: Am80, etc.) to immunodeficiencies such as vitamin A deficiency, keratosis of epithelial tissue, xerosis, allergic disease, rheumatism, and bone disease.
- a retinoic acid-retinoic acid-like biological activity for example, 4-[(5,6,7,8-tetrahydro-5,5,8,8 -tetramethyl-2-naphthalenyl) carbamoy ⁇ ”benzoic acid: Am80, etc.
- immunodeficiencies such as vitamin A deficiency, keratosis of epithelial tissue, xerosis, allergic disease, rheumatism, and bone
- the compound of the present invention enhances the action of retinoic acid already present in the living body even when retinoid is not administered for the treatment or prevention of the above-mentioned diseases, and thus is used for the treatment and prevention of the above-mentioned diseases. It is also possible to administer the compounds of the invention themselves.
- the compounds of the present invention not only have an effect of enhancing action on retinoids, but also have a nuclear receptor 'superfamily' (Evans, RM, Science, 240, p. 889, 1988) can also be used to enhance the action of physiologically active substances such as steroid compounds, steroid compounds that exhibit physiological effects by binding to receptors, vitamin D compounds such as vitamin 1) 0, and thyroxine.
- the medicament comprising the compound of the present invention may be administered as it is, but is preferably administered as an oral or parenteral pharmaceutical composition which can be produced by a method well known to those skilled in the art. New It can also be used as a pharmaceutical composition in the form of a so-called combination by blending it with a medicine containing retinoic acid such as retinoic acid as an active ingredient.
- Pharmaceutical compositions suitable for oral administration include, for example, tablets, capsules, powders, fine granules, granules, solutions, and syrups.
- Pharmaceutical compositions suitable for parenteral administration include Examples thereof include injections, suppositories, inhalants, eye drops, nasal drops, ointments, creams, and patches.
- the above-mentioned pharmaceutical composition can be produced by adding pharmacologically and pharmaceutically acceptable additives.
- pharmacologically and pharmaceutically acceptable additives include, for example, Excipients, disintegrants or disintegration aids, binders, lubricants, coatings, pigments, diluents, bases, solubilizers or dissolution aids, isotonic agents, pH regulators, stabilizers , A propellant, and an adhesive.
- the dosage of the medicament of the present invention is not particularly limited, and a combination of a medicament of the present invention with a medicament of the present invention and a medicament containing a retinoid such as retinoic acid as an active ingredient, or
- a medicament of the present invention for enhancing the action of retinoic acid already existing in the living body without using the medicament containing the same
- an appropriate dose can be easily selected in any administration method.
- it can be used in the range of about 0.01 to about 000 mg per adult per day.
- the medicament of the present invention can be administered during the retinoid administration period or before or after the administration period. is there.
- Example 1 4- [5H-2,3- (2,5-dimethyl-2,5-hexano) -5-methyldibenzo [b, e] [1,4] diazepine-U-yl] benzoic acid (HX600) production
- 6-Bromo-1,2,3,4-tetrahydro-1,1,4,4-tetramethylnaphthalene 2.30 g (8.61 mmol), o-Nitroaline 4 ⁇ 30 g (31.2 mmol), K 2 C0 3 4.30 g (31.2 mmol),
- ⁇ -NHR CDC1 3 8.59 (dd, 1H, 8 ⁇ , 1.5Hz), 8.56 (brs, 1H), 8.ll (d, 2H, 8.8Hz), 7.86 (d, 2H, 8.4Hz), 7.30 ( d, 1H, 8.8Hz), 7.16 (m, 1H), 7.07 (dd, 1H, 8.1H, 1.5Hz), 7.04 (d, 1H, 2.6Hz), 6.90 (dd, 1H, 8.1Hz, 1.5Hz) , 6.81 (dd, 1H, 8.
- 1,2,3,4-Tetrahydro-1,1,4,4-tetramethylunaphthalene 6.0 g (32.0 dandelion ⁇ ) was added to 10 ml of cuprate sulfonic acid at 0 ° C and stirred for 1 hour. Pour the reaction solution into ice water Extracted with ethyl acetate. The organic phase was washed with saturated saline, dried, and the solvent was distilled off under reduced pressure. 10 g (15.2 mraol) of zinc dust and 20 ml of ethanol were added to the residue, and 40 ml of concentrated hydrochloric acid was further added over 5 minutes, followed by heating under reflux for 1 hour and 25 minutes. Ice water and ethyl acetate were added to the reaction solution for extraction, and the organic phase was washed with saturated saline. After drying, the solvent was distilled off under reduced pressure to obtain 6.82 g of a crude product.
- 5 mg (0.515 mmol) and 177 rag (0.77 mmol, 1.5 eq) of lealanine ethyl ester hydrochloride 5 ml of pyridine was added, and the mixture was refluxed for 16 hours.
- Dilute hydrochloric acid was added to the reaction solution, and the mixture was extracted with dichloromethane. The organic phase was washed with water and saturated saline, dried and concentrated.
- the degree of differentiation into granulocyte cells was determined by observing the morphology of the nucleus and measuring the reducing ability of nitrobulotetrazolium (NBT). This method is a well-known method that well reflects the activity of retinoids to induce cell differentiation. The results are shown in Table 2 below (in the table, the NBT positive rate is a value indicating the ratio of differentiated cells to living cells in percentage). Table 2 Retinoid (M) Test compound (M) NBT positive rate (3 ⁇ 4) In the absence of retinoic acid 14
- the compound of the present invention When the compound of the present invention was co-present with retinoic acid or Am80, the ratio of differentiated cells was significantly increased, indicating that the compound of the present invention enhanced the cell differentiation-inducing effect of retinoic acid or Am80. it is obvious.
- the compound LE135 used as a control is a compound known as an agonite of retinoide (Eyrol les, L., et al., J. Med. Chem., 37, pp.
- the compound of the present invention enhances the action of retinoids such as retinoic acid, and is useful as a medicament such as a retinoid action enhancer.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thin Film Transistor (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69619711T DE69619711T2 (de) | 1995-09-21 | 1996-09-20 | Retinoid-potenzierende verbindungen |
DK96931263T DK0906907T3 (da) | 1995-09-21 | 1996-09-20 | Forbindelser, der potenserer retinoid |
EP96931263A EP0906907B1 (en) | 1995-09-21 | 1996-09-20 | Compounds potentiating retinoid |
AT96931263T ATE214055T1 (de) | 1995-09-21 | 1996-09-20 | Retinoid-potenzierende verbindungen |
KR10-1998-0702114A KR100484294B1 (ko) | 1995-09-21 | 1996-09-20 | 레티노이드작용증강성화합물 |
AU70015/96A AU7001596A (en) | 1995-09-21 | 1996-09-20 | Compounds potentiating retinoid |
EA199800318A EA002123B1 (ru) | 1995-09-21 | 1996-09-20 | Соединения, усиливающие активность ретиноидов |
NO981269A NO981269L (no) | 1995-09-21 | 1998-03-20 | Forbindelser som forsterker virkningen av retinoider |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP24263995 | 1995-09-21 | ||
JP7/242639 | 1995-09-21 | ||
JP15058296 | 1996-06-12 | ||
JP8/150582 | 1996-06-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997011061A1 true WO1997011061A1 (fr) | 1997-03-27 |
Family
ID=26480129
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1996/002709 WO1997011061A1 (fr) | 1995-09-21 | 1996-09-20 | Composes a potentialisation de retinoide |
Country Status (13)
Country | Link |
---|---|
US (3) | US5929069A (ja) |
EP (1) | EP0906907B1 (ja) |
KR (1) | KR100484294B1 (ja) |
CN (1) | CN1121395C (ja) |
AT (1) | ATE214055T1 (ja) |
AU (1) | AU7001596A (ja) |
CA (1) | CA2233012A1 (ja) |
DE (1) | DE69619711T2 (ja) |
DK (1) | DK0906907T3 (ja) |
EA (1) | EA002123B1 (ja) |
NO (1) | NO981269L (ja) |
TW (1) | TW420667B (ja) |
WO (1) | WO1997011061A1 (ja) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999024415A1 (fr) * | 1997-11-12 | 1999-05-20 | Institute Of Medicinal Molecular Design, Inc. | Agonistes du recepteur du retinoide |
US6083973A (en) * | 1998-03-09 | 2000-07-04 | Syntex (U.S.A.) Inc. | Methods for inhibiting mucin secretion using RAR α selective antagonists |
US6121256A (en) * | 1995-09-21 | 2000-09-19 | Institute Of Medicinal Molecular Design, Inc. | Compounds activating pharmacological effect of retinoids |
EP1036565A1 (en) * | 1997-12-05 | 2000-09-20 | Institute of Medicinal Molecular Design, Inc. | Preventives/remedies for diabetes |
US6869959B1 (en) | 1999-04-28 | 2005-03-22 | Institute Of Medicinal Molecular Design Inc. | Heterocyclic carboxylic acid derivatives |
WO2005099759A1 (ja) * | 2004-04-16 | 2005-10-27 | Institute Of Medicinal Molecular Design. Inc. | 動脈硬化症の予防及び/又は治療のための医薬 |
WO2009022722A1 (ja) | 2007-08-15 | 2009-02-19 | Research Foundation Itsuu Laboratory | 3環系アミン化合物 |
US8796261B2 (en) | 2010-12-02 | 2014-08-05 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
US9249161B2 (en) | 2010-12-02 | 2016-02-02 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
US9328117B2 (en) | 2011-06-17 | 2016-05-03 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
US9422292B2 (en) | 2011-05-04 | 2016-08-23 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
US9493483B2 (en) | 2012-06-06 | 2016-11-15 | Constellation Pharmaceuticals, Inc. | Benzo [C] isoxazoloazepine bromodomain inhibitors and uses thereof |
US9624244B2 (en) | 2012-06-06 | 2017-04-18 | Constellation Pharmaceuticals, Inc. | Benzo [B] isoxazoloazepine bromodomain inhibitors and uses thereof |
US9969747B2 (en) | 2014-06-20 | 2018-05-15 | Constellation Pharmaceuticals, Inc. | Crystalline forms of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[C]isoxazolo[4,5-e]azepin-4-yl)acetamide |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5127096B2 (ja) * | 1999-04-30 | 2013-01-23 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | アポトーシスにより誘導される自己免疫疾患を処置するためのベンゾジアゼピンの使用 |
US7572788B2 (en) | 1999-04-30 | 2009-08-11 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
US20060025388A1 (en) | 1999-04-30 | 2006-02-02 | Glick Gary D | Compositions and methods relating to novel compounds and targets thereof |
US20070161105A1 (en) | 2003-03-20 | 2007-07-12 | Reasearch Foundation Itsuu Laboratory | Method of forming organ |
GB0308335D0 (en) | 2003-04-10 | 2003-05-14 | Novartis Ag | Organic compounds |
CN100548288C (zh) | 2004-03-10 | 2009-10-14 | 财团法人乙卯研究所 | 记忆固定促进剂 |
JP2008545757A (ja) | 2005-06-01 | 2008-12-18 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 溶媒和されていないベンゾジアゼピン組成物および方法 |
EP1930001A4 (en) * | 2005-09-09 | 2010-07-21 | Kemphys Ltd | PHARMACEUTICAL AGENT FOR THE PREVENTION AND / OR TREATMENT OF THOROTIC DISEASES |
CA2779041A1 (en) | 2005-11-01 | 2007-05-10 | The Regents Of The University Of Michigan | Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties |
MX2008015488A (es) | 2006-06-09 | 2009-02-12 | Univ Michigan | Composiciones y metodos relacionados con compuestos novedosos y objetivos de los mismos. |
JP2008081427A (ja) * | 2006-09-27 | 2008-04-10 | R&R Inc | 分泌障害性疾患の予防及び/又は治療のための医薬 |
US7902260B2 (en) * | 2007-02-28 | 2011-03-08 | Kemphys Ltd. | Medicament for preventive and/or therapeutic treatment of lower urinary tract symptom |
AU2008226532B2 (en) | 2007-03-09 | 2011-09-22 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
MX2010002732A (es) | 2007-09-14 | 2010-06-02 | Univ Michigan | Inhibidores de f1f0-atpasa y metodos relacionados. |
KR20100083819A (ko) | 2007-11-06 | 2010-07-22 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 피부 병태의 치료에 유용한 벤조디아제피논 화합물 |
WO2010030891A2 (en) | 2008-09-11 | 2010-03-18 | The Regents Of The University Of Michigan | Aryl guanidine f1f0-atpase inhibitors and related methods |
WO2010121164A2 (en) | 2009-04-17 | 2010-10-21 | The Regents Of The University Of Michigan | 1,4-benzodiazepinone compounds and their use in treating cancer |
EP2470020A4 (en) | 2009-09-18 | 2013-03-13 | Univ Michigan | BENZODIAZEPINONE COMPOUNDS AND TREATMENT METHODS THEREWITH |
WO2011037128A1 (ja) | 2009-09-28 | 2011-03-31 | 日本曹達株式会社 | 含窒素ヘテロ環化合物およびその塩ならびに農園芸用殺菌剤 |
JP5856064B2 (ja) | 2009-11-17 | 2016-02-09 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 治療特性を有する1,4−ベンゾジアゼピン−2,5−ジオンおよび関連化合物 |
JP5856063B2 (ja) | 2009-11-17 | 2016-02-09 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 治療特性を有する1,4−ベンゾジアゼピン−2,5−ジオンおよび関連化合物 |
WO2012112623A2 (en) * | 2011-02-14 | 2012-08-23 | Sloan-Kettering Institute For Cancer Research | Rxrg modulators for the treatment of cancer |
CN103304494B (zh) * | 2013-06-20 | 2015-05-27 | 河北大学 | 茚(1,2-b)喹喔啉-11-酮肟衍生物及其制备方法和用途 |
KR200489267Y1 (ko) | 2018-09-20 | 2019-05-23 | 김은진 | 폭 조절형 옷걸이 |
KR200490993Y1 (ko) | 2019-06-14 | 2020-02-04 | 이현봉 | 구김방지기능을 구비한 바지걸이 |
CN114702454A (zh) * | 2022-03-29 | 2022-07-05 | 江西师范大学 | 5-烷基-11-芳基-5H-二苯并[b,e][1,4]二氮杂卓衍生物的制备方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04211071A (ja) * | 1990-03-05 | 1992-08-03 | Hokuriku Seiyaku Co Ltd | 多環式化合物 |
DK0906907T3 (da) * | 1995-09-21 | 2002-04-22 | Inst Med Molecular Design Inc | Forbindelser, der potenserer retinoid |
JP4204657B2 (ja) * | 1997-12-05 | 2009-01-07 | 有限会社ケムフィズ | 糖尿病の予防・治療剤 |
-
1996
- 1996-09-20 DK DK96931263T patent/DK0906907T3/da active
- 1996-09-20 AT AT96931263T patent/ATE214055T1/de not_active IP Right Cessation
- 1996-09-20 CA CA002233012A patent/CA2233012A1/en not_active Abandoned
- 1996-09-20 EA EA199800318A patent/EA002123B1/ru not_active IP Right Cessation
- 1996-09-20 EP EP96931263A patent/EP0906907B1/en not_active Expired - Lifetime
- 1996-09-20 DE DE69619711T patent/DE69619711T2/de not_active Expired - Lifetime
- 1996-09-20 TW TW085111550A patent/TW420667B/zh not_active IP Right Cessation
- 1996-09-20 AU AU70015/96A patent/AU7001596A/en not_active Abandoned
- 1996-09-20 WO PCT/JP1996/002709 patent/WO1997011061A1/ja active IP Right Grant
- 1996-09-20 US US08/710,657 patent/US5929069A/en not_active Expired - Lifetime
- 1996-09-20 KR KR10-1998-0702114A patent/KR100484294B1/ko not_active IP Right Cessation
- 1996-09-20 CN CN96198386A patent/CN1121395C/zh not_active Expired - Fee Related
-
1998
- 1998-03-20 NO NO981269A patent/NO981269L/no unknown
-
1999
- 1999-04-09 US US09/288,618 patent/US6121256A/en not_active Expired - Fee Related
-
2001
- 2001-04-20 US US09/838,272 patent/US6476017B2/en not_active Expired - Fee Related
Non-Patent Citations (4)
Title |
---|
CHEMICAL & PHARMACEUTICAL BULLETIN, Vol. 43, No. 10, p. 1827-1829, (October 1995). * |
CHEMICAL ABSTRACTS, Vol. 66, p. 1046, (1967), Abstract No. 10838a; & ACTA CHEM. SCAND., Vol. 20, No. 6, p. 1631-44, (1966). * |
JOURNAL OF MEDICINAL CHEMISTRY, Vol. 37, No. 10, p. 1508-1517, (13 May 1994). * |
JOURNAL OF ORGANIC CHEMISTRY, Vol. 37, No. 24, p. 3755-3770 (1972). * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6121256A (en) * | 1995-09-21 | 2000-09-19 | Institute Of Medicinal Molecular Design, Inc. | Compounds activating pharmacological effect of retinoids |
WO1999024415A1 (fr) * | 1997-11-12 | 1999-05-20 | Institute Of Medicinal Molecular Design, Inc. | Agonistes du recepteur du retinoide |
EP1036565A1 (en) * | 1997-12-05 | 2000-09-20 | Institute of Medicinal Molecular Design, Inc. | Preventives/remedies for diabetes |
EP1036565A4 (en) * | 1997-12-05 | 2003-04-23 | Inst Med Molecular Design Inc | PREVENTIVE / HEALING AGENTS FOR SUGAR DISEASE |
US6083973A (en) * | 1998-03-09 | 2000-07-04 | Syntex (U.S.A.) Inc. | Methods for inhibiting mucin secretion using RAR α selective antagonists |
US6869959B1 (en) | 1999-04-28 | 2005-03-22 | Institute Of Medicinal Molecular Design Inc. | Heterocyclic carboxylic acid derivatives |
WO2005099759A1 (ja) * | 2004-04-16 | 2005-10-27 | Institute Of Medicinal Molecular Design. Inc. | 動脈硬化症の予防及び/又は治療のための医薬 |
US8143260B2 (en) | 2007-08-15 | 2012-03-27 | Research Foundation Itsuu Laboratory | Tricyclic amine compound |
WO2009022722A1 (ja) | 2007-08-15 | 2009-02-19 | Research Foundation Itsuu Laboratory | 3環系アミン化合物 |
US8796261B2 (en) | 2010-12-02 | 2014-08-05 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
US9249161B2 (en) | 2010-12-02 | 2016-02-02 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
US9522920B2 (en) | 2010-12-02 | 2016-12-20 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
US9422292B2 (en) | 2011-05-04 | 2016-08-23 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
US9328117B2 (en) | 2011-06-17 | 2016-05-03 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
US9493483B2 (en) | 2012-06-06 | 2016-11-15 | Constellation Pharmaceuticals, Inc. | Benzo [C] isoxazoloazepine bromodomain inhibitors and uses thereof |
US9624244B2 (en) | 2012-06-06 | 2017-04-18 | Constellation Pharmaceuticals, Inc. | Benzo [B] isoxazoloazepine bromodomain inhibitors and uses thereof |
US9925197B2 (en) | 2012-06-06 | 2018-03-27 | Constellation Pharmaceuticals, Inc. | Benzo [C] isoxazoloazepine bromodomain inhibitors and uses thereof |
US9969747B2 (en) | 2014-06-20 | 2018-05-15 | Constellation Pharmaceuticals, Inc. | Crystalline forms of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[C]isoxazolo[4,5-e]azepin-4-yl)acetamide |
Also Published As
Publication number | Publication date |
---|---|
US5929069A (en) | 1999-07-27 |
DE69619711D1 (de) | 2002-04-11 |
AU7001596A (en) | 1997-04-09 |
TW420667B (en) | 2001-02-01 |
EA002123B1 (ru) | 2001-12-24 |
EA199800318A1 (ru) | 1998-10-29 |
CN1202160A (zh) | 1998-12-16 |
US6121256A (en) | 2000-09-19 |
DK0906907T3 (da) | 2002-04-22 |
EP0906907A4 (ja) | 1999-04-07 |
EP0906907B1 (en) | 2002-03-06 |
DE69619711T2 (de) | 2002-10-17 |
US20010039272A1 (en) | 2001-11-08 |
EP0906907A1 (en) | 1999-04-07 |
ATE214055T1 (de) | 2002-03-15 |
NO981269L (no) | 1998-05-20 |
KR19990063661A (ko) | 1999-07-26 |
US6476017B2 (en) | 2002-11-05 |
KR100484294B1 (ko) | 2005-09-09 |
CN1121395C (zh) | 2003-09-17 |
CA2233012A1 (en) | 1997-03-27 |
NO981269D0 (no) | 1998-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1997011061A1 (fr) | Composes a potentialisation de retinoide | |
JP4929472B2 (ja) | カルボン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤 | |
KR100483442B1 (ko) | 레티노이드형생리활성을갖는테트라히드로나프타렌,크로만,티오크로만및1,2,3,4-테트라히드퀴놀린카르복실산의아릴또는헤테로아릴아미드 | |
WO1999024415A1 (fr) | Agonistes du recepteur du retinoide | |
JPH07179430A (ja) | 三環式ベンズアゼピン・バソプレツシン拮抗薬 | |
FR2530247A1 (fr) | Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique | |
JP2001055367A (ja) | ヒトペルオキシゾーム増殖薬活性化受容体(PPAR)αアゴニストとしての置換フェニルプロピオン酸誘導体 | |
WO1989005812A1 (en) | Thienodiazepine compounds and their medicinal use | |
JP3865829B2 (ja) | レチノイド作用増強性化合物 | |
JPH08503202A (ja) | 治療剤 | |
FR2703995A1 (fr) | 5-acylamino 1,2,4-thiadiazoles, leur préparation et compositions pharmaceutiques en contenant. | |
JPS6160074B2 (ja) | ||
IL98454A (en) | History of 2-aminoalkyl-5-arylacil-1,3-dioxane, their preparation and pharmaceutical preparations containing them | |
MXPA03008229A (es) | Trienos fluorados y su uso como moduladores rxr. | |
JP4005160B2 (ja) | レチノイドアンタゴニスト | |
JPH03223277A (ja) | ベンゾチオフェン誘導体 | |
JP4121853B2 (ja) | レチノイド作用性物質 | |
JPH05345785A (ja) | トリアゾロオキサゼピン化合物 | |
JPS62149672A (ja) | 4H−ベンゾ〔4,5〕シクロヘプタ〔1,2−b〕チオフエン誘導体 | |
CH635590A5 (fr) | Derives de l'isoquinoleine, leur preparation et compositions pharmaceutiques qui les contiennent. | |
US4124596A (en) | Thienothienylcarbonyl-phenylalkanoic acids and derivatives thereof | |
US4183944A (en) | Thienothienylcarbonyl-phenylalkanoic acids and derivatives thereof | |
JP2510893B2 (ja) | ナフチルスルホニルアルキルカルボン酸誘導体 | |
JPH0436268A (ja) | フェニルスルフィニルアルキルカルボン酸誘導体 | |
JPH03133952A (ja) | フェニルスルホニルアルキルカルボン酸誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 96198386.8 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AU BA BB BG BR CA CN CU CZ EE GE HU IL IS KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK TR TT UA UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1996931263 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019980702114 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2233012 Country of ref document: CA Ref document number: 2233012 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 199800318 Country of ref document: EA |
|
WWP | Wipo information: published in national office |
Ref document number: 1996931263 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019980702114 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1996931263 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1019980702114 Country of ref document: KR |